Radiotherapy
252
87
102
43
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
1.6%
4 terminated out of 252 trials
91.5%
+5.0% vs benchmark
11%
27 trials in Phase 3/4
2%
1 of 43 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 43 completed trials
Clinical Trials (252)
Neoadjuvant vs. Intraoperative vs. Adjuvant Resection Cavity Radiotherapy of Brain Metastases
Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment
Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer
Nutritional Status of Head and Neck Cancer Patients
MRinRT: Swansea University and SWWCC Collaboration Study.
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
Measuring Fluid Buildup in Cancer Patients
Comparison of Patient Understanding and Anxiety According to the Delivery Method of Educational Videos
Virtual Vs Telephone Education in Radiotherapy
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
The Effect of Radiotherapy After Separation Surgery for Spinal Metastases
A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)
Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases
HPV After chemoRadioTherapy
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL